210.40
전일 마감가:
$207.92
열려 있는:
$208
하루 거래량:
4.26M
Relative Volume:
0.78
시가총액:
$371.68B
수익:
$58.33B
순이익/손실:
$3.73B
주가수익비율:
100.19
EPS:
2.1
순현금흐름:
$18.24B
1주 성능:
-0.09%
1개월 성능:
+10.03%
6개월 성능:
+2.62%
1년 성능:
+7.80%
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ABBV
Abbvie Inc
|
210.40 | 367.30B | 58.33B | 3.73B | 18.24B | 2.10 |
![]()
LLY
Lilly Eli Co
|
732.58 | 656.17B | 53.26B | 13.80B | -50.20M | 15.30 |
![]()
JNJ
Johnson Johnson
|
177.17 | 422.54B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
NVS
Novartis Ag Adr
|
126.55 | 244.83B | 53.40B | 13.68B | 16.89B | 6.9231 |
![]()
MRK
Merck Co Inc
|
84.12 | 207.84B | 63.43B | 16.42B | 14.72B | 6.49 |
애브비 Stock (ABBV) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-08-12 | 재개 | Piper Sandler | Overweight |
2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
2024-12-10 | 재개 | BofA Securities | Neutral |
2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-11-15 | 개시 | Wolfe Research | Outperform |
2024-11-04 | 업그레이드 | Argus | Hold → Buy |
2024-10-17 | 개시 | Bernstein | Mkt Perform |
2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
2023-11-09 | 개시 | Deutsche Bank | Hold |
2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
2023-10-20 | 재개 | UBS | Neutral |
2023-09-29 | 개시 | Raymond James | Outperform |
2023-07-25 | 개시 | William Blair | Mkt Perform |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
2023-03-01 | 개시 | Guggenheim | Buy |
2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
2022-11-18 | 개시 | Credit Suisse | Outperform |
2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
2022-05-23 | 개시 | SVB Leerink | Underperform |
2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
2022-04-06 | 재개 | Morgan Stanley | Overweight |
2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
2022-02-03 | 재확인 | Barclays | Equal Weight |
2022-02-03 | 재확인 | BofA Securities | Neutral |
2022-02-03 | 재확인 | Goldman | Neutral |
2022-01-13 | 개시 | Redburn | Buy |
2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
2021-12-09 | 재개 | Wells Fargo | Overweight |
2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
2021-07-27 | 재개 | Truist | Buy |
2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
2020-11-10 | 재개 | Bernstein | Outperform |
2020-09-29 | 개시 | Berenberg | Hold |
2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
2020-06-02 | 업그레이드 | Argus | Hold → Buy |
2020-05-18 | 재개 | BofA/Merrill | Neutral |
2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
2020-05-11 | 재개 | Morgan Stanley | Overweight |
2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
2020-02-27 | 개시 | Barclays | Equal Weight |
2020-02-06 | 개시 | Mizuho | Buy |
2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
2019-12-26 | 재확인 | Cowen | Outperform |
2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2019-05-28 | 개시 | Goldman | Neutral |
2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
Is AbbVie Stock Underperforming the S&P 500? - MSN
Stock Analysis | Abbvie OutlookA Technical Wait-and-See But Strong Fundamentals Draw Attention - AInvest
Analyzing drawdowns of AbbVie Inc. with statistical toolsTrade Exit Summary & Verified Stock Trade Ideas - Newser
Why AbbVie's Workplace Excellence Drives Long-Term Value for Investors - AInvest
AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work - PR Newswire
What indicators show strength in AbbVie Inc.2025 Retail Activity & Verified Entry Point Signals - Newser
What recovery options are there for AbbVie Inc.2025 Stock Rankings & Smart Money Movement Tracker - Newser
Pharma and Industrial Sector Catalysts: Evaluating AbbVie and Hawkins' Strategic Momentum - AInvest
Visual trend scoring systems applied to AbbVie Inc.Trade Analysis Summary & Short-Term High Return Strategies - Newser
What machine learning models say about AbbVie Inc.Weekly Trend Summary & Real-Time Stock Price Movement Reports - Newser
Signal strength of AbbVie Inc. stock in tech scannersMarket Volume Summary & Free Verified High Yield Trade Plans - Newser
Tools to assess AbbVie Inc.’s risk profile2025 Top Gainers & Technical Pattern Based Signals - Newser
How to escape a deep drawdown in AbbVie Inc.July 2025 Levels & Verified Swing Trading Watchlist - Newser
Key deals this week: Hawkins, Canada Goose, AbbVie, Verint and more (BX:NYSE) - Seeking Alpha
Analyzing recovery setups for AbbVie Inc. investors2025 Technical Overview & Safe Swing Trade Setups - Newser
Is AbbVie Inc. trending in predictive chart models2025 Performance Recap & Reliable Intraday Trade Plans - Newser
Visual analytics tools that track AbbVie Inc. performanceQuarterly Trade Summary & Weekly Top Gainers Trade List - Newser
Is AbbVie Stock Underperforming The S&P 500? - Barchart.com
Quantitative breakdown of AbbVie Inc. recent movePortfolio Value Report & Low Risk High Win Rate Stock Picks - Newser
BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory - insights.citeline.com
Detecting price anomalies in AbbVie Inc. with AIWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
Deal Dispatch: PepsiCo, Sycamore, Dr. Phil, SSENSE, Bain's Chindata Lead M&A, Bankruptcy Moves - Benzinga
AbbVie’s Promising Study on ABBV-453 for Multiple Myeloma: A Potential Game-Changer - TipRanks
AbbVie Inc. stock prediction for this weekMarket Activity Recap & Precise Swing Trade Entry Alerts - Newser
AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin - Seeking Alpha
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025? - sharewise.com
Will a bounce in AbbVie Inc. offer an exitWeekly Trend Summary & Technical Entry and Exit Tips - Newser
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
DBS Bank Adjusts Price Target on AbbVie to $208 From $188, Maintains Hold Rating - MarketScreener
J&J halts studies for potential rival to AbbVie’s Humira after trial setback - Seeking Alpha
AbbVie, Nokia, Lululemon Athletica: 'Mad Money' Lightning Round - TheStreet
Assessing AbbVie’s Valuation After $1.2B Bretisilocin Acquisition Announcement - Yahoo Finance
2 Reasons to Watch ABBV and 1 to Stay Cautious - FinancialContent
Risk adjusted return profile for AbbVie Inc. analyzedPortfolio Value Summary & Safe Capital Growth Stock Tips - Newser
Rx Rundown: AbbVie, Novartis, MannKind and more - Medical Marketing and Media
AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush? - microdose.buzz
Who Owns AbbVie? Biggest Shareholders and Recent Insider Trades - TIKR.com
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):